Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2018	Jul. 31, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus (Q1,Q2,Q3,FY)	Q2
Trading Symbol	EHTH
Entity Registrant Name	eHealth, Inc.
Entity Central Index Key	0001333493
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding (in shares)		19,175,834

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 30,774	$ 40,293
Accounts receivable	846	1,475
Commissions receivable - current	88,246	109,666
Prepaid expenses and other current assets	5,441	4,305
Total current assets	125,307	155,739
Commissions receivable - non-current	179,150	169,751
Property and equipment, net	4,640	4,705
Other assets	9,035	7,287
Intangible assets, net	13,342	7,540
Goodwill	40,233	14,096
Total assets	371,707	359,118
Current liabilities:
Accounts payable	2,154	3,246
Accrued compensation and benefits	12,032	15,498
Accrued marketing expenses	2,742	4,693
Earnout liability - current	15,766	0
Other current liabilities	3,523	2,008
Total current liabilities	36,217	25,445
Earnout liability - non-current	14,434	0
Deferred income taxes - non-current	38,607	45,089
Other non-current liabilities	2,197	1,920
Stockholders’ equity:
Common stock	30	30
Additional paid-in capital	292,159	281,706
Treasury stock, at cost	(199,998)	(199,998)
Retained earnings	187,866	204,725
Accumulated other comprehensive income	195	201
Total stockholders’ equity	280,252	286,664
Total liabilities and stockholders’ equity	$ 371,707	$ 359,118

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue
Commission	$ 30,646	$ 32,451	$ 71,353	$ 71,288
Other	2,011	2,115	4,374	4,834
Total revenue	32,657	34,566	75,727	76,122
Operating costs and expenses:
Cost of revenue	151	56	303	237
Marketing and advertising	14,606	14,240	29,608	29,295
Customer care and enrollment	13,219	12,012	26,458	24,121
Technology and content	7,287	7,932	15,628	16,004
General and administrative	11,240	10,534	21,931	20,526
Change in fair value of earnout liability	2,500	0	2,500	0
Restructuring charges	9	0	1,865	0
Acquisition costs	18	0	76	0
Amortization of intangible assets	547	260	998	520
Total operating costs and expenses	49,577	45,034	99,367	90,703
Loss from operations	(16,920)	(10,468)	(23,640)	(14,581)
Other income (expense), net	296	298	480	575
Loss before benefit from income taxes	(16,624)	(10,170)	(23,160)	(14,006)
Benefit from income taxes	(4,610)	(8,664)	(6,301)	(13,580)
Net loss	$ (12,014)	$ (1,506)	$ (16,859)	$ (426)
Net loss per share:
Basic (in usd per share)	$ (0.63)	$ (0.08)	$ (0.89)	$ (0.02)
Diluted (in usd per share)	$ (0.63)	$ (0.08)	$ (0.89)	$ (0.02)
Weighted-average number of shares used in per share amounts:
Basic (in shares)	19,063	18,481	18,968	18,424
Diluted (in shares)	19,063	18,481	18,968	18,424
Comprehensive loss
Foreign currency translation adjustment, net of taxes	$ (71)	$ 10	$ (6)	$ 18
Comprehensive loss	$ (12,085)	$ (1,496)	$ (16,865)	$ (408)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating activities
Net loss	$ (16,859)	$ (426)
Adjustments to reconcile net loss to net cash provided by operating activities:
Deferred income taxes	(6,482)	(12,131)
Depreciation and amortization	1,250	1,513
Amortization of internally developed software	1,011	651
Amortization of intangible assets	998	520
Stock-based compensation expense	5,932	4,702
Change in fair value of earnout liability	2,500	0
Other non-cash items	376	(52)
Changes in operating assets and liabilities:
Accounts receivable	629	1,386
Commissions receivable	27,495	20,145
Prepaid expenses and other assets	(1,120)	(88)
Accounts payable	(1,202)	(2,798)
Accrued compensation and benefits	(3,598)	(799)
Accrued marketing expenses	(1,951)	(2,771)
Deferred revenue	376	(490)
Accrued expense and other liabilities	1,081	(1,902)
Net cash provided by operating activities	10,436	7,460
Investing activities
Capitalized internal-use software and website development costs	(2,763)	(1,665)
Purchases of property and equipment and other assets	(1,122)	(1,105)
Acquisition of business, net of cash acquired	(14,929)	0
Net cash used in investing activities	(18,814)	(2,770)
Financing activities
Proceeds from exercise of common stock options	668	49
Cash used to net-share settle equity awards	(1,742)	(396)
Principal payments in connection with capital leases	(52)	(62)
Net cash used in financing activities	(1,126)	(409)
Effect of exchange rate changes on cash and cash equivalents	(15)	18
Net increase (decrease) in cash and cash equivalents	(9,519)	4,299
Cash and cash equivalents at beginning of period	40,293	61,781
Cash and cash equivalents at end of period	$ 30,774	$ 66,080

Summary of Business and Significant Accounting Policies

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Summary of Business and Significant Accounting Policies

Description of Business — eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is a leading private health insurance exchange for individuals, families and small businesses in the United States. Through our website addresses (www.eHealth.com, www.eHealthInsurance.com, www.eHealthMedicare.com, www.Medicare.com, www.PlanPrescriber.com and www.GoMedigap.com), consumers can get quotes from leading health insurance carriers, compare plans side-by-side, and apply for and purchase Medicare-related, individual and family, small business and ancillary health insurance plans. We actively market the availability of Medicare-related insurance plans and offer Medicare plan comparison tools and educational materials for Medicare-related insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans. Our ecommerce technology also enables us to deliver consumers’ health insurance applications electronically to health insurance carriers. We are licensed to market and sell health insurance in all 50 states and the District of Columbia.

Basis of Presentation — The accompanying condensed consolidated balance sheets as of December 31, 2017 and June 30, 2018, the condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2017 and 2018 and the condensed consolidated statements of cash flows for the six months ended June 30, 2017 and 2018, respectively, are unaudited. Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), as discussed in detail below under Adoption of New Accounting Standards. All amounts and disclosures set forth in this Quarterly Report on Form 10-Q have been updated to comply with Topic 606. Except for the impact of the adoption of Topic 606, the condensed consolidated balance sheet data as of December 31, 2017 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the Securities and Exchange Commission on March 19, 2018. The accompanying statements should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K.

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance to such rules and regulations. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2017 and include all adjustments necessary for the fair presentation of our financial position as of December 31, 2017 and June 30, 2018, our results of operations for the three and six months ended June 30, 2017 and 2018 and our cash flows for the six months ended June 30, 2017 and 2018. The results for the three and six months ended June 30, 2018 are not necessarily indicative of the results to be expected for any subsequent period or for the fiscal year ending December 31, 2018 and therefore should not be relied upon as an indicator of future results.

Principles of Consolidation — The condensed consolidated financial statements include the accounts of eHealth, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Seasonality — A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter.

The majority of our individual and family health insurance plans are sold in the fourth quarter during the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of these open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state.

Recent Accounting Pronouncements Not Yet Adopted

Leases (Topic 842) — In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize a right-of-use asset and lease liability for all leases with terms of more than 12 months. Recognition, measurement, and presentation of expenses will depend on classification as a finance or operating lease. The guidance also eliminates existing real estate-specific provisions for all entities. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. Early adoption is permitted. We expect to adopt this new accounting standard in the first quarter of 2019. While we are currently evaluating the impact of adopting ASU 2016-02, based on the lease portfolio as of June 30, 2018, we anticipate recording lease assets and liabilities of approximately $31.7 million on its Condensed Balance Sheets, with no material impact to its condensed consolidated statements of comprehensive loss. However, the ultimate impact of adopting ASU 2016-02 will depend on our lease portfolio as of the adoption date.

Adoption of New Accounting Standards

Compensation — Stock Compensation (Topic 718) — In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. We adopted ASU 2017-09 in the first quarter of 2018. The adoption of this new standard did not have a material impact on our condensed consolidated financial statements.

Statement of Cash Flows (Topic 230) — In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which clarifies guidance on the classification and presentation of restricted cash in the statement of cash flows. Under ASU 2016-18, changes in restricted cash and restricted cash equivalents would be included along with those of cash and cash equivalents in the statement of cash flows. As a result, entities would no longer present transfers between cash/equivalents and restricted cash/equivalents in the statement of cash flows. In addition, a reconciliation between the balance sheet and the statement of cash flows would be disclosed when the balance sheet includes more than one line item for cash/equivalents and restricted cash/equivalents. We adopted ASU 2016-18 in the first quarter of 2018. The adoption of this new standard did not have a material impact on our condensed consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance on how certain cash receipts and cash payments are presented on the statement of cash flows. We adopted ASU 2016-15 in the first quarter of 2018. The adoption of this new standard did not have a material impact on our condensed consolidated financial statements.

Goodwill Impairment (Topic 350) — In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment (Topic 350). Under the new standard, goodwill impairment would be measured as the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying value of goodwill. ASU 2017-04 eliminates existing guidance that requires an entity to determine goodwill impairment by calculating the implied fair value of goodwill by hypothetically assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. ASU 2017-04 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019 with early adoption permitted for annual goodwill impairment tests performed after January 1, 2017. The standard must be applied prospectively. We early adopted ASU 2017-04 in the first quarter of 2018. The adoption of this new standard has not materially impacted our condensed consolidated financial statements.

Revenue Recognition (Topic 606) — In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), requiring an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. In April 2016, the FASB issued ASU No. 2016-10, Identifying Performance Obligations and Licensing. ASU 2016-10 provides guidance in identifying performance obligations and determining the appropriate accounting for licensing arrangements.

The effective date and transition requirements for ASU 2016-10 are the same as the effective date and transition requirements in Topic 606 (and any other Topic amended by ASU 2014-09). ASU 2014-09 may be adopted retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method). We adopted ASC 2014-09 effective January 1, 2018, using the full retrospective method to restate each prior reporting period presented. The adoption of this standard had a material impact on our condensed consolidated balance sheets and condensed consolidated statements of comprehensive loss, but had no impact on total net cash provided by (used in) operating, investing, or financing activities within the condensed consolidated statements of cash flows.

Change in Significant Accounting Policies

Except for the accounting policies for revenue recognition, commissions receivable and deferred revenue that were updated as a result of adopting Topic 606, there have been no changes to our significant accounting policies described in the Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 19, 2018, that have had a material impact on our condensed consolidated financial statements and related notes.

Revenue Recognition Policy

We are compensated by the receipt of commission payments from health insurance carriers whose health insurance policies are purchased through our ecommerce platforms or our customer care centers. We may also receive commission bonuses based on our attaining predetermined target sales levels for Medicare, individual and family, small business and ancillary health insurance products, or other objectives, as determined by the health insurance carrier, which we recognize as commission revenue when we achieve the predetermined target sales levels or other objectives. In addition, we also generate revenue from non-commission revenue sources, which include online sponsorship and advertising, technology licensing and lead referrals.

The core principle of Topic 606 is to recognize revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration the entity expects to be entitled to in exchange for those goods or services. Accordingly, we recognize revenue for our services in accordance with the following five steps outlined in Topic 606:

•

Identification of the contract, or contracts, with a customer. A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance, and (iii) we determine that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

•

Identification of the performance obligations in the contract. Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract.


•	Determination of the transaction price. The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer.

•

Allocation of the transaction price to the performance obligations in the contract. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis.


•	Recognition of revenue when, or as, we satisfy a performance obligation. We satisfy performance obligations either over time or at a point in time, as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised good or service to the customer.

Commission Revenue — Our commission revenue is primarily comprised of commissions paid to us by health insurance carriers related to insurance plans that have been purchased by a member through our health insurance exchange service. We define a member as an individual currently covered by an insurance plan, which include Medicare-related, individual and family, small business and ancillary plans. We are compensated by the health insurance carrier, which we define as our customer.

We typically enter into contractual relationships with health insurance carriers that are non-exclusive and terminable on short notice by either party for any reason. In addition, health insurance carriers often have the ability to terminate or amend our agreements unilaterally on short notice, including provisions in our agreements relating to the commission rates paid to us by the health insurance carriers. The amendment or termination of an agreement we have with a health insurance carrier may adversely impact the commissions we are paid on health insurance plans purchased from the carrier by means of our health insurance exchange services.

For both Medicare Advantage and Medicare Part D prescription drug plans, we receive a fixed, annual commission payment from insurance carriers once the plan is approved by the carrier and either a fixed, monthly or annual commission payment beginning with and subsequent to the second plan year. In the first plan year of a Medicare Advantage and Medicare Part D prescription drug plan, after the health insurance carrier approves the application but during the effective year of the plan, we are paid a fixed commission that is prorated for the number of months remaining in the calendar year. Additionally, if the plan is the first Medicare Advantage or Medicare Part D plan issued to the member, we may receive a higher commission rate that covers a full twelve-month period, regardless of the month the plan was effective. We earn commission revenue for Medicare Advantage and Medicare Part D prescription drug plans for which we are the broker of record, typically until either the policy is cancelled or we otherwise do not remain the agent on the policy.

For individual and family, Medicare Supplement, small business and ancillary plans, our commissions generally represent a flat amount per member per month or a percentage of the premium amount collected by the carrier during the period that a member maintains coverage under a plan. Premium-based commissions are reported to us after the premiums are collected by the carrier, generally on a monthly basis. We generally continue to receive the commission payment from the relevant insurance carrier until the health insurance plan is cancelled or we otherwise do not remain the agent on the policy.

We utilize a practical expedient to estimate commission revenue for each insurance product by applying the use of a portfolio approach to group approved members by the effective month of the relevant policy (referred to as a “cohort”). This allows us to estimate the commissions we expect to collect for each approved member cohort by evaluating various factors, including but not limited to, contracted commission rates, carrier mix and expected member churn.

For Medicare-related, individual and family and ancillary health insurance plans, our services are complete once a submitted application is approved by the relevant health insurance carrier. Accordingly, we recognize commission revenue based upon the total estimated lifetime commissions we expect to receive for selling the plan after the carrier approves an application, net of a constraint. We refer to these estimated and constrained lifetime values as the "constrained lifetime value" for the plan. We provide annual services in selling and renewing small business health insurance plans; therefore, we recognize small business health insurance plan commission revenue at the time the plan is approved by the carrier, and when it renews each year thereafter, equal to the estimated commissions we expect to collect from the plan over the following 12-months. Our estimate of commission revenue for each product line is based on a number of assumptions, which include, but are not limited to, estimating conversion of an approved member to a paying member, forecasting member churn and forecasting the commission amounts likely to be received per member. These assumptions are based on historical trends and incorporate management’s judgment in interpreting those trends and in applying constraints discussed below. To the extent we make changes to the assumptions, we will recognize any material impact of the changes to commission revenue in the reporting period in which the change is made, including revisions of estimated lifetime commissions either below or in excess of previously estimated constrained lifetime value recognized as revenue.

For Medicare-related, individual and family and ancillary health insurance plans, we apply constraints to determine the amount of commission revenue to recognize per approved member. The constraints are applied to help ensure that the total estimated lifetime commissions expected to be collected for an approved member’s plan are recognized as revenue only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with future commissions receivable from the plan is subsequently resolved. We evaluate the appropriateness of these constraints on at least an annual basis, including assessing factors affecting our estimate of the estimated lifetime value of commissions per approved member based on current trends impacting our business and assessing whether any adjustment to those constraints should be made. We update the assumptions when we observe a sufficient level of evidence that would suggest that the long term expectation of the assumption has changed.

For the three months ended June 30, 2017 and 2018, the constraints applied to the total estimated lifetime commissions we expect to receive for selling the plan after the carrier approves an application in order to derive the constrained lifetime value of commissions per approved member are as follows:



	Three Months Ended
	June 30,
	2017		2018
Medicare
Medicare Advantage	7	%	7	%
Medicare Supplement	5	%	5	%
Medicare Part D	5	%	5	%

Individual and Family
Non-Qualified Health Plans	15	%	15	%
Qualified Health Plans	20	%	20	%

Ancillary	10	%	10	%

Small Business	—		—

Other Revenue — Our sponsorship and advertising program allows carriers to purchase advertising space in specific markets in a sponsorship area on our website. In return, we are typically paid a monthly fee, which is recognized over the period that advertising is displayed. Such revenue often includes a performance fee component based on metrics such as submitted health insurance applications and is recognized when the performance obligations are fulfilled and control has been transferred. We also offer Medicare advertising services, which include website development, hosting and maintenance. In these instances, we are typically paid a fixed, up-front fee, which we recognize as revenue over the service period as the performance obligations are satisfied.

Our commercial technology licensing business allows carriers the use of our ecommerce platform to offer their own health insurance policies on their websites and allows agents to utilize our technology to power their online quoting, content and application submission processes. Typically, we are paid a one-time implementation fee, which we recognize upon transfer of control at a point in time, commencing once the technology is available for use by the third party. Variable consideration in the form of performance fees based on metrics such as submitted health insurance applications are recognized upon achieving the metrics. The metrics used to calculate performance fees for both sponsorship and advertising and technology licensing are based on performance criteria that are either measured based on data tracked by us, or data tracked by the third party.

Deferred revenue includes deferred technology licensing implementation fees and amounts billed or collected from sponsorship or technology licensing customers in advance of our performing our service for such customers. It also includes the amount by which both unbilled and billed services provided under our technology licensing arrangements exceed the straight-line revenue recognized to date.

Some of our contracts with customers contain multiple performance obligations. We allocate revenue to all performance obligations within an arrangement with multiple deliverables at the inception of the arrangement using the relative standalone selling price method.

Disaggregation of Revenue

The table below depicts the disaggregation of revenue by product for the three and six months ended June 30, 2017 and 2018 and is consistent with how we evaluate our financial performance:



	Three Months Ended					Six Months Ended
	June 30,					June 30,
	2017		2018			2017		2018
Commission Revenue:
Medicare
Medicare Advantage	$	18,677	$	17,738		$	37,882	$	39,673
Medicare Supplement	2,886		5,355			6,800		10,947
Medicare Part D	1,203		715			2,581		1,874
Total Medicare	22,766		23,808			47,263		52,494
Individual and Family ⁽¹⁾
Non-Qualified Health Plans	1,988		1,069			5,761		2,510
Qualified Health Plans	2,634		1,675			5,766		3,837
Total Individual and Family	4,622		2,744			11,527		6,347
Ancillary
Short-term	1,029		1,293			2,875		2,543
Dental	1,003		147			2,850		1,366
Vision	282		391			852		731
Other	762		(118		)	1,527		2,653
Total Ancillary	3,076		1,713			8,104		7,293
Small Business	1,532		1,772			3,456		4,131
Commission Bonus	455		609			938		1,088
Total Commission Revenue	32,451		30,646			71,288		71,353
Other Revenue	2,115		2,011			4,834		4,374
Total Revenue	$	34,566	$	32,657		$	76,122	$	75,727



(1)	We define our Individual and Family Plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both Qualified and Non-Qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase Non-Qualified health plans cannot receive a subsidy in connection with the purchase of Non-Qualified plans.

Book-of-Business Transfers

We entered into several agreements with a broker partner, whereby the partner transferred certain of its existing Medicare plan members to us as the broker of record on the underlying policies. The first of these book-of-business transfers occurred in November 2010 and the most recent in June 2012. Total consideration paid by us for these books-of-business amounted to $13.9 million. Consideration paid for these books-of-business is included within commissions receivable in the accompanying condensed consolidated balance sheets. The consideration we paid to the broker partner was based on the discounted commissions expected to be received over the remaining life of each transferred Medicare plan member. As we receive commission payments from health insurance carriers for these plan members, we reduce commissions receivable for the discounted commissions expected to be received, with the remaining margin earned recorded to other income (expense), net in the condensed consolidated statements of comprehensive income (loss). The margin earned and recorded to other income (expense), net for these books-of-business for the three and six months ended June 30, 2017 and 2018 totaled $0.5 million and $0.4 million, respectively.

Incremental Costs to Obtain a Contract

We reviewed our sales compensation plans, which are directed at converting leads into approved members, and concluded that they are fulfillment costs and not costs to obtain a contract with a health insurance carrier, which we define as our customer. Additionally, we reviewed compensation plans related to personnel responsible for identifying new health insurance carriers and entering into contracts with new health insurance carriers and concluded that no incremental costs are incurred to obtain such contracts.

Income Taxes

As described in more detail in Note 6 - Income Taxes, as a result of the adoption of Topic 606, we recorded a significant deferred tax liability on our recasted opening balance sheet related to the resulting accelerated revenue recognition under Topic 606. Additionally, as a result of the deferred tax liability, we re-evaluated the need for the valuation allowance recorded against our U.S. deferred tax assets. As a result of this evaluation, we determined that the deferred tax liability is a source of income that can be used to support realization of deferred tax assets on a more-likely-than-not level and accordingly reversed our previously recorded valuation allowance as of January 1, 2015, the earliest period to which the retrospective the adoption of Topic 606 was applied.

Impact to Previously Reported Results

The adoption of ASU 2014-09 impacted our reported results as follows (in thousands, except per share amounts):



	December 31, 2017
Balance Sheets	As Reported			ASC 606 Adoption Adjustment			As Adjusted
Accounts receivable	$	9,894		$	(8,419	)	$	1,475
Commissions receivable - current	$	—		$	109,666		$	109,666
Prepaid expenses and other current assets	$	4,845		$	(540	)	$	4,305
Commissions receivable - non-current	$	—		$	169,751		$	169,751
Other assets	$	7,317		$	(30	)	$	7,287
Accrued marketing expenses	$	4,088		$	605		$	4,693
Other current liabilities	$	3,815		$	(1,807	)	$	2,008
Deferred income taxes - non-current	$	—		$	45,089		$	45,089
Non-current liabilities	$	900		$	1,020		$	1,920
Retained earnings (accumulated deficit)	$	(20,796	)	$	225,521		$	204,725



	Three Months Ended June 30, 2017									Six Months Ended June 30, 2017
Statements of Operations	As Reported			ASC 606 Adoption Adjustment			As Adjusted			As Reported			ASC 606 Adoption Adjustment			As Adjusted
Revenue	$	27,957		$	6,609		$	34,566		$	106,896		$	(30,774	)	$	76,122
Cost of revenue	$	204		$	(148	)	$	56		$	1,833		$	(1,596	)	$	237
Other income, net	$	90		$	208		$	298		$	116		$	459		$	575
Provision (benefit) from income taxes	$	125		$	(8,789	)	$	(8,664	)	$	(1,448	)	$	(12,132	)	$	(13,580	)
Net income (loss)	$	(17,260	)	$	15,754		$	(1,506	)	$	16,161		$	(16,587	)	$	(426	)
Net income (loss) per diluted share	$	(0.93	)	$	0.85		$	(0.08	)	$	0.86		$	(0.90	)	$	(0.02	)



	Three Months Ended June 30, 2017									Six Months Ended June 30, 2017
Segment Information	As Reported			ASC 606 Adoption Adjustment			As Adjusted			As Reported		ASC 606 Adoption Adjustment			As Adjusted
Revenue
Medicare	$	11,014		$	13,148		$	24,162		$	68,988	$	(19,416	)	$	49,572
Individual, Family and Small Business	16,943			(6,539		)	10,404			37,908		(11,358		)	26,550
Total revenue	$	27,957		$	6,609		$	34,566		$	106,896	$	(30,774	)	$	76,122

Segment profit (loss)
Medicare segment profit (loss)	$	(15,107	)	$	13,094		$	(2,013	)	$	15,588	$	(18,530	)	$	(2,942	)
Individual, Family and Small Business segment profit	8,404			(6,339		)	2,065			19,483		(10,648		)	8,835
Total segment profit (loss)	$	(6,703	)	$	6,755		$	52		$	35,071	$	(29,178	)	$	5,893

Acquisition

6 Months Ended

Jun. 30, 2018

Business Combinations [Abstract]

Acquisition

On January 22, 2018, we completed our acquisition of all outstanding membership interests of Wealth, Health and Life Advisors, LLC, more commonly known as GoMedigap, a technology-enabled provider of Medicare Supplement enrollment services. This acquisition is expected to enhance our growing presence in the Medicare Supplement market and put us in a stronger position with carriers and strategic partners. The acquisition consideration consisted of cash of $15.0 million, less $0.1 million of cash acquired, and 294,637 shares of our common stock. In addition, the members of GoMedigap are entitled to receive earnout payments ("Earnout Consideration") consisting of up to $20 million in cash and 589,275 shares of our common stock. The Earnout Consideration will become payable, subject to the terms and conditions of the purchase agreement relating to the acquisition, upon the final determination of the achievement of certain milestones in 2018 and 2019.

The GoMedigap acquisition was accounted for using the acquisition method of accounting under ASC 805, Business Combinations. The acquisition method of accounting requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The major classes of assets and liabilities to which we have preliminarily allocated the acquisition consideration were as follows (in thousands):



Acquisition Consideration
Cash paid	$	15,000
Fair value of equity awards issued to GoMedigap members ⁽¹⁾	5,595
Estimated fair value of earnout liability	27,700
	$	48,295
Allocation
Cash and cash equivalents	$	71
Commission receivable - current	4,371
Prepaid expenses and other current assets	11
Commission receivable - non-current	11,103
Property and equipment, net	174
Accounts payable	(110		)
Accrued compensation and benefits	(132		)
Other current liabilities	(131		)
Net tangible assets acquired	15,357
Intangible assets	6,800
Goodwill	26,138
Total intangible assets acquired	32,938
Total net assets acquired	$	48,295

(1) The fair value of equity awards issued was determined based on the January 22, 2018 closing price of our common stock of $18.99.

The acquisition consideration allocation as of the date of the acquisition was based on a preliminary valuation and is subject to revision as more detailed analyses are completed and additional information about the fair value of assets acquired and liabilities assumed becomes available. Additional information that result in adjustments to the provisional current and non-current commissions receivable amounts recognized as of the acquisition date may result in a corresponding adjustment to goodwill in the period in which new information becomes available.

Goodwill and Intangible Assets — Goodwill represents the excess of the purchase price of the acquired business over the acquisition date fair value of the net assets acquired. Goodwill is primarily attributable to the assembled workforce, new product development capabilities and anticipated synergies and economies of scale expected from the operations of the combined company. The goodwill was assigned to our Medicare segment. Goodwill is tested for impairment on an annual basis in the fourth quarter of each year or whenever events or changes in circumstances indicate that the asset may be impaired. Factors that we consider in deciding when to perform an impairment test include significant negative industry or economic trends or significant changes or planned changes in our use of the intangible assets. Goodwill will be deductible for tax purposes over 15 years.

Earnout liability — The earnout liability represents the fair value of the Earnout Consideration payable and will be adjusted to fair value at each reporting date until settled. Changes in fair value will be recognized in income (loss) from operations. The earnout liability will be adjusted to the extent the specified enrollment targets are not achieved.

Fair Value Measurements — The assets acquired and liabilities assumed of GoMedigap have been recognized at fair value in accordance with ASC 820, Fair Value Measurement. ASC 820 defines fair value as the price that would be received to sell an asset or would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 requires three levels of hierarchy, which prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy level assigned to each asset and liability is based on the assessment of the transparency and reliability of inputs used in the valuation of such items based on the lowest level of input that is significant to fair value measurement. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and lowest priority to unobservable inputs (Level 3 measurements).

Assets acquired and liabilities assumed measured and reported at fair value are classified in one of the following categories based on inputs:



Level 1	Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2	Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability.
Level 3	Unobservable inputs for the asset or liability.

The fair value of prepaid expenses and other current assets, property and equipment, net, accounts payable, accrued compensation and benefits and other current liabilities approximated their carrying value at the date of acquisition. The fair value of commissions receivable was determined using a discount rate of interest, which is a Level 2 input. Intangible assets and the earnout liability were valued using Level 3 inputs.

The fair values of the acquired intangible assets were determined using the profit allocation method, which is based on determining the estimated royalties we are relieved from paying because we own the assets.

The fair value of the earnout liability was measured using probability-weighted analysis and is discounted using a rate that appropriately captures the risk associated with the obligation. Key assumptions included new enrollments and volatility for the years ending December 31, 2018 and 2019 and eHealth’s simulated stock price at the time of payment. The earnout liability was part of the acquisition consideration and will be adjusted to fair value at each reporting date until settled. The fair value adjustments to the earnout liability during both the three and six months ended June 30, 2018 totaled $2.5 million. We will continue to update the key assumptions each period and record any fair value adjustments, as necessary.

Following are the details of the acquisition consideration allocated to the intangible assets acquired (in thousands):



Technology	$	2,000
Trade names, trademarks and website addresses	4,800
Total intangible assets	$	6,800

We are amortizing the existing technology and trade name using the straight-line method over an estimated life of 3 and 10 years, respectively. The estimated useful lives are based on the time periods during which the intangibles are expected to result in incremental cash flows.

We incurred $0.1 million of acquisition-related costs during the six months ended June 30, 2018, which were expensed as incurred.

Balance Sheet Accounts

6 Months Ended

Jun. 30, 2018

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Accounts

Cash and Cash Equivalents — As of December 31, 2017 and June 30, 2018, our cash equivalents consisted of money market accounts that invested in U.S. government-sponsored enterprise bonds and discount notes, U.S. government treasury bills and notes and repurchase agreements collateralized by U.S. government obligations. As of December 31, 2017 and June 30, 2018, our cash equivalents carried no unrealized gains or losses and we did not realize any significant gains or losses on sales of cash equivalents during the three or six months ended June 30, 2017 and 2018.

As of December 31, 2017 and June 30, 2018, our cash and cash equivalent balances were invested as follows (in thousands):



	December 31, 2017		June 30, 2018
Cash	$	5,098	$	7,396
Money market funds	35,195		23,378
Total cash and cash equivalents	$	40,293	$	30,774

Prepaid Expenses and Other Current Assets — Prepaid expenses and other current assets consisted of the following (in thousands):



	December 31, 2017		June 30, 2018
Prepaid maintenance contracts	$	1,945	$	1,849
Prepaid insurance	490		1,169
Prepaid rent	311		508
Other current assets	1,559		1,915
Total prepaid expenses and other current assets	$	4,305	$	5,441

Intangible Assets — The carrying amounts, accumulated amortization, net carrying value and weighted average remaining life of our definite-lived amortizable intangible assets, as well as our indefinite-lived intangible trademarks, are presented in the tables below for (dollars in thousands, weighted-average remaining life in years):



	December 31, 2017							June 30, 2018
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Weighted-Average Remaining Life
Technology	$	1,700	$	(1,700	)	$	—	$	3,700	$	(1,978	)	$	1,722	2.6 years
Pharmacy and customer relationships	10,100		(7,884		)	2,216		10,100		(8,358		)	1,742		1.8 years
Trade names, trademarks and website addresses	907		(697		)	210		5,707		(943		)	4,764		9.3 years
Total intangible assets subject to amortization	$	12,707	$	(10,281	)	2,426		$	19,507	$	(11,279	)	8,228
Indefinite-lived trademarks and domain names						5,114							5,114		Indefinite
Total intangible assets						$	7,540						$	13,342

As of June 30, 2018, expected amortization expense in future periods is as follows (in thousands):



Years Ending December 31,	Technology		Pharmacy and Customer Relationships		Trade Names, Trademarks and Website Addresses		Total
2018	$	333	$	475	$	284	$	1,092
2019	667		950		570		2,187
2020	667		317		510		1,494
2021	55		—		480		535
2022	—		—		480		480
Thereafter	—		—		2,440		2,440
Total	$	1,722	$	1,742	$	4,764	$	8,228

Fair Value Measurements

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

We define fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques we use to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We classify the inputs used to measure fair value into the following hierarchy:



Level 1		Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2		Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability.
Level 3		Unobservable inputs for the asset or liability.

The following table is a summary of financial assets measured at fair value on a recurring basis and their classification within the fair value hierarchy (in thousands).



	December 31, 2017						June 30, 2018
	Carrying Value		Level 1		Total		Carrying Value		Level 1		Level 3		Total
Assets
Money market funds	$	35,195	$	35,195	$	35,195	$	23,378	$	23,378	$	—	$	23,378
Total assets measured and recorded at fair value	$	35,195	$	35,195	$	35,195	$	23,378	$	23,378	$	—	$	23,378

Liability
Earnout liability - current	$	—	$	—	$	—	$	15,766	$	—	$	15,766	$	15,766
Earnout liability - non-current	—		—		—		14,434		—		14,434		14,434
Total liabilities measured and recorded at fair value	$	—	$	—	$	—	$	30,200	$	—	$	30,200	$	30,200

Our cash equivalents were invested in money market funds and were classified as Level 1. We endeavor to utilize the best available information in measuring fair value. We used observable prices in active markets in determining the classification of our money market funds as Level 1.

The earnout liability represents the fair value of the Earnout Consideration payable to acquire GoMedigap and will be adjusted to fair value at each reporting date until settled. See Note 2 - Acquisition for additional information on the earnout consideration.

We measure the earnout liability using internally developed assumptions, therefore it is classified as Level 3. The fair value of the earnout liability was measured using probability-weighted analysis and is discounted using a rate that appropriately captures the risk associated with the obligation. Key assumptions included new enrollments and volatility for the years ending December 31, 2018 and 2019 and our simulated stock price at the time of payment.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholder's Equity

6 Months Ended

Jun. 30, 2018

Stockholders' Equity Note [Abstract]

Stockholder's Equity

2014 Equity Incentive Plan — The following table summarizes activity under our 2014 Equity Incentive Plan (the “2014 Plan”) for the six months ended June 30, 2018 (in thousands):



	Shares Available for Grant
Shares available for grant December 31, 2017	1,409
Restricted stock units granted ¹	(499	)
Options granted²	(111	)
Restricted stock units cancelled ³	112
Options cancelled	17
Shares available for grant June 30, 2018	928


(1)	Includes grants of restricted stock units with service, performance-based or market-based vesting criteria.


(2)	Includes grants of stock options with service, performance-based or market-based vesting criteria.


(3)	Includes cancelled restricted stock units with service, performance-based or market-based vesting criteria.

The following table summarizes stock option activity (in thousands, except weighted-average exercise price and weighted-average remaining contractual life data):



	Number of Stock Options ¹		Weighted Average Exercise Price		Weighted-Average Remaining Contractual Life (years)	Aggregate Intrinsic Value ²
Balance outstanding at December 31, 2017	983		$	17.38	4.6	$	2,522
Granted	111		$	15.69
Exercised	(46	)	$	13.47
Cancelled	(95	)	$	25.19
Balance outstanding at June 30, 2018	953		$	16.45	4.7	$	6,344
Vested and expected to vest at June 30, 2018	909		$	16.45	4.7	$	6,083
Exercisable at June 30, 2018	437		$	17.38	3.6	$	2,945


(1)	Includes certain stock options with service, performance-based or market-based vesting criteria.


(2)	The aggregate intrinsic value is calculated as the difference between the closing price of our common stock as of December 31, 2017 and June 30, 2018 and the exercise price multiply by number of in-the-money options.

The following table summarizes restricted stock unit activity (in thousands, except weighted-average grant date fair value and weighted-average remaining contractual life data):



	Number of Restricted Stock Units ¹		Weighted-Average Grant Date Fair Value		Weighted-Average Remaining Service Period	Aggregate Intrinsic Value ²
Unvested as of December 31, 2017	1,745		$	14.24	2.3	$	30,313
Granted	499		$	14.03
Vested	(264	)	$	14.04
Cancelled	(112	)	$	16.05
Unvested as of June 30, 2018	1,868		$	14.92	5.8	$	41,286


(1)	Includes certain restricted stock units with service, performance-based or market-based vesting criteria.


(2)	The aggregate intrinsic value is calculated as the product of our closing stock price as of December 31, 2017 and June 30, 2018 and the number of restricted stock units outstanding as of December 31, 2017 and June 30, 2018, respectively.

Stock Repurchase Programs — We had no stock repurchase activity during the six months ended June 30, 2018. In addition to 10,663,888 shares repurchased under our past repurchase programs as of June 30, 2018, we have in treasury 660,493 shares that were previously surrendered by employees to satisfy tax withholdings due in connection with the vesting of certain restricted stock units. As of December 31, 2017 and June 30, 2018, we had a total of 11,237,995 shares and 11,324,381 shares, respectively, held in treasury.

For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method.

Stock-Based Compensation Expense — The following table summarizes stock-based compensation expense recorded during the three and six months ended June 30, 2017 and 2018 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2018		2017		2018
Common stock options	$	714	$	436	$	901	$	934
Restricted stock units	1,855		2,695		3,801		4,998
Total stock-based compensation expense	$	2,569	$	3,131	$	4,702	$	5,932

The following table summarizes stock-based compensation expense by operating function for the three and six months ended June 30, 2017 and 2018 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2018		2017		2018
Marketing and advertising	$	220	$	553	$	435	$	923
Customer care and enrollment	124		206		136		371
Technology and content	274		383		668		726
General and administrative	1,951		1,989		3,463		3,661
Restructuring	—		—		—		251
Total stock-based compensation expense	$	2,569	$	3,131	$	4,702	$	5,932

During the six months ended June 30, 2018, as part of our workforce reduction as discussed in Note 10 - Restructuring Charges, we accelerated the vesting dates of certain stock options and restricted stock units granted to a former employee. We recorded $0.3 million of incremental stock-based compensation expense in connection with this modification.

Income Taxes

6 Months Ended

Jun. 30, 2018

Income Tax Disclosure [Abstract]

Income Taxes

The following table summarizes our benefit from income taxes and our effective tax rates for the three and six months ended June 30, 2017 and 2018 (in thousands, except effective tax rate):



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2018			2017			2018
Loss before benefit from income taxes	$	(10,170	)	$	(16,624	)	$	(14,006	)	$	(23,160	)
Benefit from income taxes	$	(8,664	)	$	(4,610	)	$	(13,580	)	$	(6,301	)
Effective tax rate	85.2		%	27.7		%	97.0		%	27.2		%

For the three months ended June 30, 2018, we recognized a benefit from income taxes of $4.6 million, representing an effective tax rate of 28%, which was higher than the statutory federal tax rate due primarily to stock-based compensation adjustments, non-deductible lobbying expenses, and foreign income inclusions, partially offset by research and development credits. For the three months ended June 30, 2017, we recognized a benefit from income taxes of $8.7 million, representing an effective tax rate of 85%, which was higher than the statutory federal tax rate due primarily to the release of a liability for unrecognized tax benefits, research and development credits and stock-based compensation adjustments, partially offset by non-deductible lobbying expenses.

For the six months ended June 30, 2018, we recognized a benefit from income taxes of $6.3 million, representing an effective tax rate of 27%, which was higher than the statutory federal tax rate due primarily to stock-based compensation adjustments, non-deductible lobbying expenses, and foreign income inclusions, partially offset by research and development credits. For the six months ended June 30, 2017, we recognized a benefit from income taxes of $13.6 million, representing an effective tax rate of 97%, which was higher than the statutory federal tax rate due primarily to the release of a liability for unrecognized tax benefits, research and development credits and stock-based compensation adjustments, partially offset by non-deductible lobbying expenses.

As a result of our adoption of Topic 606 using the full retrospective method, we recognized a significant deferred tax liability in our recasted opening balance sheet due to the resulting acceleration of revenue recognition while revenue for tax purposes will continue to be recognized as we collect cash. This deferred tax liability is a source of income that can be used to support the realizability of our deferred tax assets. As a result of the significantly increased deferred tax liability, we reversed the valuation allowance recorded against our U.S. deferred tax assets as of January 1, 2015, the earliest period to which the retrospective adoption of Topic 606 was applied. We continue to recognize all our deferred tax assets as of June 30, 2018 as we believe it is more likely than not that the net deferred tax assets will be fully realized.

The Tax Cuts and Jobs Act ("Jobs Act") legislation was passed in December 2017, which has various implications on our income tax provision accrual. The main impact of the Jobs Act on our provision (benefit) for income taxes is the decrease in our statutory federal income tax rate from 35% to 21% and the change in the deferred income tax rate used in determining deferred tax balances. Our estimated annual effective tax rate has been adjusted for the impact of the Jobs Act including, among other things, certain limitations on deductions and taxes on Global Intangible Low-Taxed Income ("GILTI") earned by our China subsidiary. Given the complexity of the GILTI provisions, we are still evaluating their effects and as of June 30, 2018, we have included GILTI related to current-year operations only in our estimated annual effective tax rate and have not provided for additional GILTI on deferred items. The effects of other provisions of the tax reform legislation are not expected to have a material impact on our condensed consolidated financial statements. However, the final impact of the Jobs Act may differ from our estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued, and resulting actions we may take.

Net Loss Per Share

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net loss per share is computed giving effect to all potential dilutive common stock equivalent shares, including options and restricted stock units. The dilutive effect of outstanding awards is reflected in diluted net loss per share by application of the treasury stock method.

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share amounts):



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2018			2017			2018
Basic:
Numerator:
Net loss	$	(1,506	)	$	(12,014	)	$	(426	)	$	(16,859	)
Denominator:
Weighted-average number of common stock shares outstanding	18,481			19,063			18,424			18,968
Net loss per share—basic:	$	(0.08	)	$	(0.63	)	$	(0.02	)	$	(0.89	)
Diluted:
Numerator:
Net loss	$	(1,506	)	$	(12,014	)	$	(426	)	$	(16,859	)
Denominator:
Net weighted average number of common stock shares outstanding	18,481			19,063			18,424			18,968
Dilutive effect of potential common stock	—			—			—			—
Total common stock shares used in per share calculation	18,481			19,063			18,424			18,968
Net loss per share—diluted:	$	(0.08	)	$	(0.63	)	$	(0.02	)	$	(0.89	)

For the three and six months ended June 30, 2017 and 2018, we had securities outstanding that could potentially dilute earnings per share, but the shares from the assumed conversion or exercise of these securities were excluded in the computation of diluted net loss per share as their effect would have been anti-dilutive. The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net income loss per share consisted of the following (in thousands):



	Three Months Ended June 30,		Six Months Ended June 30,
	2017	2018	2017	2018
Common stock options	841	1,021	916	1,013
Restricted stock units	1,094	1,632	1,109	1,581
Total	1,935	2,653	2,025	2,594

Commitments and Contingencies

6 Months Ended

Jun. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Legal Proceedings

On January 26, 2017, a purported class action lawsuit was filed against us in the Superior Court of the State of California, County of Santa Clara. The complaint alleges that we negligently failed to take necessary precautions required to protect from unauthorized disclosure of personally identifiable information contained on 2016 Form W-2s for current and former employees. The complaint purports to allege causes of action against us for negligence, violation of Section 17200 et seq. of the California Business & Professions Code, declaratory relief and breach of implied contract. The complaint seeks actual damages, punitive damages, statutory damages, costs, including experts’ fees and attorneys’ fees, pre-judgment and post-judgment interest as prescribed by law and equitable, injunctive and declaratory relief as appropriate. In April 2017, an additional purported class action lawsuit was filed against us in the Superior Court of State of California, County of Santa Clara, relating to the same circumstances. The second complaint purports to allege causes of action against us for negligence, violation of California Customer Records Act (California Civil Code Section 1798.80 et seq.), violation of the California Confidentiality of Medical Information Act (California Civil Code Section 56 et seq.), invasion of privacy by public disclosure of private facts, breach of confidentiality and violation of the California Unfair Competition Law (California Business & Professions Code Section 17200 et seq.). The causes of action for violations of the California Customer Records Act and the California Confidentiality of Medical Information Act were dismissed without prejudice. The second complaint seeks actual damages, statutory damages, restitution, disgorgement, equitable, injunctive and declaratory relief, costs, including experts’ fees and attorneys’ fees and costs of prosecuting the action, and pre-judgment and post-judgment interest as prescribed by law. In July 2017, we entered into a binding settlement term sheet where we and the plaintiffs in each of the above-described cases agreed to enter into a settlement, pursuant to which we would receive a release of all claims that were or could have been alleged related to the unauthorized disclosure at issue in each of the cases. In exchange for the release, we agreed to (i) pay, subject to an aggregate cap of $250,000, up to $2,500 to each impacted individual for reasonable, documented out-of-pocket losses or expenses related to the data security incident; (ii) offer to individuals who signed up for identity theft protection that we offered at the time of the incident a one-year extension of the identity theft protection; (iii) offer to individuals who did not sign up for identity theft protection that we offered at the time of the incident three-years of identity theft protection; and (iv) not oppose a request by class counsel for attorneys’ fees, costs and class representative enhancements of up to $245,000 in the aggregate. In December 2017, we entered into a joint stipulation for settlement of class action consistent with the settlement term sheet. The court entered an order preliminarily approving the settlement on April 23, 2018. As a result, notice of the settlement was sent to members of the class informing them of the settlement and the possible relief available to them thereunder. The settlement is subject to final approval of the court after the notice has been sent to the class and after a hearing before the court. As of June 30, 2018, we maintained an accrual in our consolidated financial statements for estimated potential damages and other amounts we expect to be required to pay in connection with the matter.

On April 6, 2018, a former California employee filed a complaint against us in the Superior Court of the State of California for the County of Sacramento. The plaintiff’s complaint was filed pursuant to the California Labor Code Private Attorneys General Act of 2004 (“PAGA”), purportedly on behalf of all current and former hourly-paid or non-exempt employees who work or have worked for us in California. The complaint alleges that we violated a number of wage and hour laws with respect to these non-exempt employees, including, among other things, the failure to comply with California law as to (i) the payment of overtime wages; (ii) the payment of minimum wages; (iii) providing uninterrupted meal and rest periods, (iv) the payment of wages earned during employment and owed upon the termination of employment; (v) providing complete and accurate wage statements, (vi) keeping of accurate payroll records; and (vii) the proper reimbursement for necessary business-related expenses and costs. The complaint seeks allegedly unpaid wages, civil penalties and costs, expenses and attorneys’ fees. Discovery has only recently commenced, and as a result we cannot estimate the likelihood of liability or the amount of potential damages.

On May 8, 2018, an individual filed a putative class action complaint against us. The complaint alleges that we violated the Telephone Consumer Protection Act, 47 U.S.C. § 227(c) and certain provisions of 47 C.F.R. § 64.1200 promulgated thereunder by initiating or causing to be initiated telephone solicitations to telephone subscribers who registered their respective telephone numbers on the National Do Not Call Registry. The complaint alleges, among other things, that we (i) made more than one unsolicited telephone call to Plaintiff and putative class members within a 12-month period without express consent to place such calls in violation of 47 U.S.C. § 227(c)(5); and (ii) initiated calls for telemarketing purposes without instituting procedures that comply with regulatory minimum standards for implementing Do Not Call in violation of 47 C.F.R. § 64.1200(d). The complaint seeks (i) an order certifying a class of individuals in the United States who (A) received more than one telephone call made by or on behalf of eHealth within a 12-month period; and (B) to a telephone number that had been registered with the National Do Not Call Registry for at least 30 days; (ii) an award of actual and statutory damages for each negligent violation to each member of the class pursuant to 47 U.S.C. § 227(b)(3)(B); (iii) an award of actual and statutory damages for each knowing and/or willful violation to each member of the class pursuant to 47 U.S.C. § 227(b)(3)(A); (iv) an injunction requiring us and our agents to cease all unsolicited telephone activities and otherwise protecting the interest of the class pursuant to 47 U.S.C. § 227(b)(3)(A); and (v) pre-judgment and post-judgment interest on monetary relief. Due to the preliminary nature of this matter and uncertainty of litigation, we are unable at this time to estimate the likelihood of liability or the amount of potential damages.

In the ordinary course of our business, we have received and may continue to receive inquiries from state regulators relating to various matters. We have become, and may in the future become, involved in litigation in the ordinary course of our business. If we are found to have violated laws or regulations in any jurisdiction, we could be subject to various fines and penalties, including revocation of our license to sell insurance in those states, and our business, operating results and financial condition would be harmed. Revocation of any of our licenses or penalties in one jurisdiction could cause our license to be revoked or for us to face penalties in other jurisdictions. In addition, without a health insurance license in a jurisdiction, carriers would not pay us commissions for the products we sold in that jurisdiction, and we would not be able to sell new health insurance products in that jurisdiction. We could also be harmed to the extent that related publicity damages our reputation as a trusted source of objective information relating to health insurance and its affordability. It could also be costly to defend ourselves regardless of the outcome.

Operating Lease Obligations

We lease our operating facilities and certain of our equipment and furniture and fixtures under various operating leases, the latest of which expires in January 2028. Certain of these leases have free or escalating rent payment provisions. We recognize rent expense on our operating leases on a straight-line basis over the terms of the leases, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements.

On April 25, 2018, we entered into a lease agreement to lease approximately 32,492 square feet of office space located in Santa Clara, California. We entered into this lease agreement as a result of the upcoming expiration of one of our leases in Mountain View, California on August 31, 2018. The term of the lease is approximately one hundred twenty-three months, commencing on an estimated date of October 1, 2018 and ending on an estimated date of December 31, 2028. Future minimum lease payments under this lease are expected to be $17.7 million.

In connection with the Santa Clara, California lease agreement, we entered into a financial guarantee consisting of a standby letter of credit for $1.5 million, which may be reduced in increments of 20% of the original amount thereof on the second, third, fourth and fifth anniversaries of the commencement date, and may be reduced by an additional 8% of the original amount on the sixth anniversary of the commencement date, subject to our compliance with the applicable conditions to such reductions set forth in the lease.

In March 2018, we entered into an agreement to lease approximately 27,000 square feet of office space in Austin, Texas. The term of this lease agreement is ninety months, commencing on an estimated date of July 15, 2018 and ending on approximately January 15, 2026. Future minimum lease payments under this lease will be approximately $4.5 million.

In connection with the Austin, Texas office lease agreement, we entered into a financial guarantee consisting of a standby letter of credit for $0.6 million, which may be reduced on the third and subsequent anniversaries of the commencement date, subject to our compliance with the applicable conditions to such reductions set forth in the lease.

In connection with our Mountain View, California lease agreement in March 2012, we entered into a financial guarantee consisting of a standby letter of credit for $0.6 million, which may be reduced in increments of 25% of the original amount thereof on the first, second and third anniversaries of the commencement date, subject to our compliance with the applicable conditions to such reductions set forth in the lease. The remaining balance on the financial guarantee is $0.1 million as of June 30, 2018.

Service and Licensing Obligations

We have entered into service and licensing agreements with third party vendors to provide various services, including network access, equipment maintenance and software licensing. The terms of these services and licensing agreements are generally up to three years. As the benefits of these agreements are experienced uniformly over the applicable contractual periods, we record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements.

The following table presents a summary of our future minimum payments under non-cancellable operating lease agreements and contractual service and licensing obligations as of June 30, 2018 (in thousands):



For the Years Ending December 31,	Operating Lease Obligations		Service and Licensing Obligations		Total Obligations
2018	$	2,177	$	963	$	3,140
2019	4,966		1,681		6,647
2020	5,238		719		5,957
2021	3,769		—		3,769
2022	3,881		—		3,881
Thereafter	13,852		—		13,852
Total	$	33,883	$	3,363	$	37,246

Operating Segments, Geographic Information and Significant Customers

6 Months Ended

Jun. 30, 2018

Segment Reporting [Abstract]

Operating Segments, Geographic Information and Significant Customers

Operating Segments

We report segment information based on how our chief executive officer, who is our chief operating decision maker ("CODM"), regularly reviews our operating results, allocates resources and makes decisions regarding our business operations. The performance measures of our segments include total revenue and profit (loss). Our business structure is comprised of two operating segments.

•Medicare

•Individual, Family and Small Business

The Medicare segment consists primarily of commissions earned from our sale of Medicare-related health insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans, and to a lesser extent, ancillary products sold to our Medicare-eligible customers, including but not limited to, dental and vision insurance, as well as our advertising program that allows Medicare-related carriers to purchase advertising on a separate website developed, hosted and maintained by us and our delivery and sale to third parties of Medicare-related health insurance leads generated by our ecommerce platforms and our marketing activities.

The Individual, Family and Small Business segment consists primarily of commissions earned from our sale of individual and family and small business health insurance plans and ancillary products sold to our non-Medicare-eligible customers, including but not limited to, short-term, dental and vision insurance. To a lesser extent, the Individual, Family and Small Business segment consists of amounts earned from our online sponsorship program that allows carriers to purchase advertising space in specific markets in a sponsorship area on our website, our licensing to third parties the use of our health insurance ecommerce technology and our delivery and sale to third parties of individual and family health insurance leads generated by our ecommerce platforms and our marketing activities.

Marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect marketing and advertising, customer care and enrollment and technology and content operating expenses are allocated to each segment based on usage. Other indirect general and administrative operating expenses are managed in a corporate shared services environment and, since they are not the responsibility of segment operating management, are not allocated to the two operating segments and are presented as a reconciling item to our consolidated financial results.

Segment profit (loss) is calculated as total revenue for the applicable segment less direct and allocated marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses, excluding stock-based compensation, depreciation and amortization expense and amortization of intangible assets.

The following table presents summary results of our operating segments for the three and six months ended June 30, 2017 and 2018 (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2018			2017			2018
Revenue
Medicare	$	24,162		$	25,468		$	49,572		$	56,231
Individual, Family and Small Business	10,404			7,189			26,550			19,496
Total revenue	$	34,566		$	32,657		$	76,122		$	75,727

Segment profit (loss)
Medicare segment profit (loss)	$	(2,013	)	$	(1,473	)	$	(2,942	)	$	1,707
Individual, Family and Small Business segment profit (loss)	2,065			(617		)	8,835			2,871
Total segment profit (loss)	52			(2,090		)	5,893			4,578
Corporate	(6,940		)	(7,994		)	(13,739		)	(15,848		)
Stock-based compensation expense	(2,569		)	(3,131		)	(4,702		)	(5,681		)
Depreciation and amortization	(751		)	(631		)	(1,513		)	(1,250		)
Change in fair value of earnout liability	—			(2,500		)	—			(2,500		)
Restructuring charges	—			(9		)	—			(1,865		)
Acquisition costs	—			(18		)	—			(76		)
Amortization of intangible assets	(260		)	(547		)	(520		)	(998		)
Other income (expense), net	298			296			575			480
Loss before benefit from income taxes	$	(10,170	)	$	(16,624	)	$	(14,006	)	$	(23,160	)

There are no internal revenue transactions between our operating segments. Our CODM does not separately evaluate assets by segment, and therefore assets by segment are not presented.

Geographic Information

Our long-lived assets consisted primarily of property and equipment and internally-developed software. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area as of December 31, 2017 and June 30, 2018 were as follows (in thousands):



	Dec 31,		June 30,
	2017		2018
United States	$	11,211	$	12,973
China	550		469
Total	$	11,761	$	13,442

Significant Customers

Substantially all revenue for the three and six months ended June 30, 2017 and 2018 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue for the three and six months ended June 30, 2017 and 2018 are presented in the table below:



	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2018		2017		2018
UnitedHealthcare ¹	21	%	24	%	22	%	23	%
Humana	16	%	14	%	16	%	14	%


(1)	UnitedHealthcare also includes other carriers owned by UnitedHealthcare.

As of June 30, 2018, our total outstanding commissions receivable balance was $267.4 million. Our contracts with the above carriers expose us to credit risk that a financial loss could be incurred if the counterparty does not fulfill its financial obligation. While we are exposed to credit losses due to the non-performance of our counterparties, we consider the risk of this remote. We estimate our maximum credit risk in determining the commissions receivable amount recorded on the balance sheet.

Restructuring Charges

6 Months Ended

Jun. 30, 2018

Restructuring and Related Activities [Abstract]

Restructuring Charges

In February 2018, our Board of Directors approved a plan to close our sales call center in Massachusetts and to terminate the employment of other employees in certain other locations. As part of this plan, we eliminated approximately 110 full-time positions, representing approximately 10% of our workforce, primarily within customer care and enrollment, and to a lesser extent, in our marketing and advertising and general and administrative groups.

We recognized $1.9 million in pre-tax restructuring charges, which included approximately $1.6 million for employee termination benefits and $0.3 million in non-cash accelerated stock based compensation in the six months ended June 30, 2018. The restructuring activities comprising the plan were completed during the three months ended June 30, 2018.

The following table summarizes the total cash and non-cash restructuring charges recognized during the six months ended June 30, 2018 (in thousands):



Employee termination costs	$	1,605
Non-cash employee termination costs - stock-based compensation	251
Other restructuring related costs	9
Total restructuring charges	$	1,865

The following table summarizes the accrued restructuring charges activity during the six months ended June 30, 2018 (in thousands):



	Six Months Ended June 30, 2018
	Beginning balance		Charges		Payments			Ending balance
Employee termination costs	$	—	$	1,605	$	(1,490	)	$	115
Accrued restructuring charges - current	$	—	$	1,605	$	(1,490	)	$	115

Summary of Business and Significant Accounting Policies (Policy)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Description of Business and Principles of Consideration

Basis of Presentation

Seasonality

Recent Accounting Pronouncements Not Yet Adopted

Adoption of New Accounting Standards

Change in Significant Accounting Policies

Revenue Recognition Policy

•


•	Determination of the transaction price. The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods or services to the customer.

•


•	Recognition of revenue when, or as, we satisfy a performance obligation. We satisfy performance obligations either over time or at a point in time, as discussed in further detail below. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised good or service to the customer.



	Three Months Ended
	June 30,
	2017		2018
Medicare
Medicare Advantage	7	%	7	%
Medicare Supplement	5	%	5	%
Medicare Part D	5	%	5	%

Individual and Family
Non-Qualified Health Plans	15	%	15	%
Qualified Health Plans	20	%	20	%

Ancillary	10	%	10	%

Small Business	—		—

Disaggregation of Revenue

The table below depicts the disaggregation of revenue by product for the three and six months ended June 30, 2017 and 2018 and is consistent with how we evaluate our financial performance:



	Three Months Ended					Six Months Ended
	June 30,					June 30,
	2017		2018			2017		2018
Commission Revenue:
Medicare
Medicare Advantage	$	18,677	$	17,738		$	37,882	$	39,673
Medicare Supplement	2,886		5,355			6,800		10,947
Medicare Part D	1,203		715			2,581		1,874
Total Medicare	22,766		23,808			47,263		52,494
Individual and Family ⁽¹⁾
Non-Qualified Health Plans	1,988		1,069			5,761		2,510
Qualified Health Plans	2,634		1,675			5,766		3,837
Total Individual and Family	4,622		2,744			11,527		6,347
Ancillary
Short-term	1,029		1,293			2,875		2,543
Dental	1,003		147			2,850		1,366
Vision	282		391			852		731
Other	762		(118		)	1,527		2,653
Total Ancillary	3,076		1,713			8,104		7,293
Small Business	1,532		1,772			3,456		4,131
Commission Bonus	455		609			938		1,088
Total Commission Revenue	32,451		30,646			71,288		71,353
Other Revenue	2,115		2,011			4,834		4,374
Total Revenue	$	34,566	$	32,657		$	76,122	$	75,727



(1)	We define our Individual and Family Plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both Qualified and Non-Qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase Non-Qualified health plans cannot receive a subsidy in connection with the purchase of Non-Qualified plans.

Book-of-Business Transfers

Incremental Costs to Obtain a Contract

Income Taxes

Summary of Business and Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Disaggregation of Revenue

The table below depicts the disaggregation of revenue by product for the three and six months ended June 30, 2017 and 2018 and is consistent with how we evaluate our financial performance:



	Three Months Ended					Six Months Ended
	June 30,					June 30,
	2017		2018			2017		2018
Commission Revenue:
Medicare
Medicare Advantage	$	18,677	$	17,738		$	37,882	$	39,673
Medicare Supplement	2,886		5,355			6,800		10,947
Medicare Part D	1,203		715			2,581		1,874
Total Medicare	22,766		23,808			47,263		52,494
Individual and Family ⁽¹⁾
Non-Qualified Health Plans	1,988		1,069			5,761		2,510
Qualified Health Plans	2,634		1,675			5,766		3,837
Total Individual and Family	4,622		2,744			11,527		6,347
Ancillary
Short-term	1,029		1,293			2,875		2,543
Dental	1,003		147			2,850		1,366
Vision	282		391			852		731
Other	762		(118		)	1,527		2,653
Total Ancillary	3,076		1,713			8,104		7,293
Small Business	1,532		1,772			3,456		4,131
Commission Bonus	455		609			938		1,088
Total Commission Revenue	32,451		30,646			71,288		71,353
Other Revenue	2,115		2,011			4,834		4,374
Total Revenue	$	34,566	$	32,657		$	76,122	$	75,727



(1)	We define our Individual and Family Plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both Qualified and Non-Qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase Non-Qualified health plans cannot receive a subsidy in connection with the purchase of Non-Qualified plans.



	Three Months Ended
	June 30,
	2017		2018
Medicare
Medicare Advantage	7	%	7	%
Medicare Supplement	5	%	5	%
Medicare Part D	5	%	5	%

Individual and Family
Non-Qualified Health Plans	15	%	15	%
Qualified Health Plans	20	%	20	%

Ancillary	10	%	10	%

Small Business	—		—

Schedule of New Accounting Pronouncements and Changes in Accounting Principles

The adoption of ASU 2014-09 impacted our reported results as follows (in thousands, except per share amounts):



	December 31, 2017
Balance Sheets	As Reported			ASC 606 Adoption Adjustment			As Adjusted
Accounts receivable	$	9,894		$	(8,419	)	$	1,475
Commissions receivable - current	$	—		$	109,666		$	109,666
Prepaid expenses and other current assets	$	4,845		$	(540	)	$	4,305
Commissions receivable - non-current	$	—		$	169,751		$	169,751
Other assets	$	7,317		$	(30	)	$	7,287
Accrued marketing expenses	$	4,088		$	605		$	4,693
Other current liabilities	$	3,815		$	(1,807	)	$	2,008
Deferred income taxes - non-current	$	—		$	45,089		$	45,089
Non-current liabilities	$	900		$	1,020		$	1,920
Retained earnings (accumulated deficit)	$	(20,796	)	$	225,521		$	204,725



	Three Months Ended June 30, 2017									Six Months Ended June 30, 2017
Statements of Operations	As Reported			ASC 606 Adoption Adjustment			As Adjusted			As Reported			ASC 606 Adoption Adjustment			As Adjusted
Revenue	$	27,957		$	6,609		$	34,566		$	106,896		$	(30,774	)	$	76,122
Cost of revenue	$	204		$	(148	)	$	56		$	1,833		$	(1,596	)	$	237
Other income, net	$	90		$	208		$	298		$	116		$	459		$	575
Provision (benefit) from income taxes	$	125		$	(8,789	)	$	(8,664	)	$	(1,448	)	$	(12,132	)	$	(13,580	)
Net income (loss)	$	(17,260	)	$	15,754		$	(1,506	)	$	16,161		$	(16,587	)	$	(426	)
Net income (loss) per diluted share	$	(0.93	)	$	0.85		$	(0.08	)	$	0.86		$	(0.90	)	$	(0.02	)



	Three Months Ended June 30, 2017									Six Months Ended June 30, 2017
Segment Information	As Reported			ASC 606 Adoption Adjustment			As Adjusted			As Reported		ASC 606 Adoption Adjustment			As Adjusted
Revenue
Medicare	$	11,014		$	13,148		$	24,162		$	68,988	$	(19,416	)	$	49,572
Individual, Family and Small Business	16,943			(6,539		)	10,404			37,908		(11,358		)	26,550
Total revenue	$	27,957		$	6,609		$	34,566		$	106,896	$	(30,774	)	$	76,122

Segment profit (loss)
Medicare segment profit (loss)	$	(15,107	)	$	13,094		$	(2,013	)	$	15,588	$	(18,530	)	$	(2,942	)
Individual, Family and Small Business segment profit	8,404			(6,339		)	2,065			19,483		(10,648		)	8,835
Total segment profit (loss)	$	(6,703	)	$	6,755		$	52		$	35,071	$	(29,178	)	$	5,893

Acquisition (Tables)

6 Months Ended

Jun. 30, 2018

Business Combinations [Abstract]

Schedule of Business Acquisitions

The major classes of assets and liabilities to which we have preliminarily allocated the acquisition consideration were as follows (in thousands):



Acquisition Consideration
Cash paid	$	15,000
Fair value of equity awards issued to GoMedigap members ⁽¹⁾	5,595
Estimated fair value of earnout liability	27,700
	$	48,295
Allocation
Cash and cash equivalents	$	71
Commission receivable - current	4,371
Prepaid expenses and other current assets	11
Commission receivable - non-current	11,103
Property and equipment, net	174
Accounts payable	(110		)
Accrued compensation and benefits	(132		)
Other current liabilities	(131		)
Net tangible assets acquired	15,357
Intangible assets	6,800
Goodwill	26,138
Total intangible assets acquired	32,938
Total net assets acquired	$	48,295

(1) The fair value of equity awards issued was determined based on the January 22, 2018 closing price of our common stock of $18.99.

Acquisition Fair Value Measurements

Assets acquired and liabilities assumed measured and reported at fair value are classified in one of the following categories based on inputs:



Level 1	Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2	Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability.
Level 3	Unobservable inputs for the asset or liability.

Schedule of Acquired Indefinite-lived Intangible Assets by Major Class

Following are the details of the acquisition consideration allocated to the intangible assets acquired (in thousands):



Technology	$	2,000
Trade names, trademarks and website addresses	4,800
Total intangible assets	$	6,800

Balance Sheet Accounts (Tables)

6 Months Ended

Jun. 30, 2018

Balance Sheet Related Disclosures [Abstract]

Schedule Of Cash And Cash Equivalents

As of December 31, 2017 and June 30, 2018, our cash and cash equivalent balances were invested as follows (in thousands):



	December 31, 2017		June 30, 2018
Cash	$	5,098	$	7,396
Money market funds	35,195		23,378
Total cash and cash equivalents	$	40,293	$	30,774

Schedule Of Prepaid Expenses And Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):



	December 31, 2017		June 30, 2018
Prepaid maintenance contracts	$	1,945	$	1,849
Prepaid insurance	490		1,169
Prepaid rent	311		508
Other current assets	1,559		1,915
Total prepaid expenses and other current assets	$	4,305	$	5,441

Schedule Of Intangible Assets

The carrying amounts, accumulated amortization, net carrying value and weighted average remaining life of our definite-lived amortizable intangible assets, as well as our indefinite-lived intangible trademarks, are presented in the tables below for (dollars in thousands, weighted-average remaining life in years):



	December 31, 2017							June 30, 2018
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Weighted-Average Remaining Life
Technology	$	1,700	$	(1,700	)	$	—	$	3,700	$	(1,978	)	$	1,722	2.6 years
Pharmacy and customer relationships	10,100		(7,884		)	2,216		10,100		(8,358		)	1,742		1.8 years
Trade names, trademarks and website addresses	907		(697		)	210		5,707		(943		)	4,764		9.3 years
Total intangible assets subject to amortization	$	12,707	$	(10,281	)	2,426		$	19,507	$	(11,279	)	8,228
Indefinite-lived trademarks and domain names						5,114							5,114		Indefinite
Total intangible assets						$	7,540						$	13,342

Schedule Of Intangible Assets Future Amortization Expense

As of June 30, 2018, expected amortization expense in future periods is as follows (in thousands):



Years Ending December 31,	Technology		Pharmacy and Customer Relationships		Trade Names, Trademarks and Website Addresses		Total
2018	$	333	$	475	$	284	$	1,092
2019	667		950		570		2,187
2020	667		317		510		1,494
2021	55		—		480		535
2022	—		—		480		480
Thereafter	—		—		2,440		2,440
Total	$	1,722	$	1,742	$	4,764	$	8,228

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

We classify the inputs used to measure fair value into the following hierarchy:



Level 1		Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2		Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability.
Level 3		Unobservable inputs for the asset or liability.

Summary of Financial Assets Measured at Fair Value on a Recurring Basis

The following table is a summary of financial assets measured at fair value on a recurring basis and their classification within the fair value hierarchy (in thousands).



	December 31, 2017						June 30, 2018
	Carrying Value		Level 1		Total		Carrying Value		Level 1		Level 3		Total
Assets
Money market funds	$	35,195	$	35,195	$	35,195	$	23,378	$	23,378	$	—	$	23,378
Total assets measured and recorded at fair value	$	35,195	$	35,195	$	35,195	$	23,378	$	23,378	$	—	$	23,378

Liability
Earnout liability - current	$	—	$	—	$	—	$	15,766	$	—	$	15,766	$	15,766
Earnout liability - non-current	—		—		—		14,434		—		14,434		14,434
Total liabilities measured and recorded at fair value	$	—	$	—	$	—	$	30,200	$	—	$	30,200	$	30,200

Stockholder's Equity (Tables)

6 Months Ended

Jun. 30, 2018

Stockholders' Equity Note [Abstract]

Schedule Of Stock Option Share Activity Under Stock Plans

The following table summarizes activity under our 2014 Equity Incentive Plan (the “2014 Plan”) for the six months ended June 30, 2018 (in thousands):



	Shares Available for Grant
Shares available for grant December 31, 2017	1,409
Restricted stock units granted ¹	(499	)
Options granted²	(111	)
Restricted stock units cancelled ³	112
Options cancelled	17
Shares available for grant June 30, 2018	928


(1)	Includes grants of restricted stock units with service, performance-based or market-based vesting criteria.


(2)	Includes grants of stock options with service, performance-based or market-based vesting criteria.


(3)	Includes cancelled restricted stock units with service, performance-based or market-based vesting criteria.

Schedule Of Activity Under Stock Plans

The following table summarizes stock option activity (in thousands, except weighted-average exercise price and weighted-average remaining contractual life data):



	Number of Stock Options ¹		Weighted Average Exercise Price		Weighted-Average Remaining Contractual Life (years)	Aggregate Intrinsic Value ²
Balance outstanding at December 31, 2017	983		$	17.38	4.6	$	2,522
Granted	111		$	15.69
Exercised	(46	)	$	13.47
Cancelled	(95	)	$	25.19
Balance outstanding at June 30, 2018	953		$	16.45	4.7	$	6,344
Vested and expected to vest at June 30, 2018	909		$	16.45	4.7	$	6,083
Exercisable at June 30, 2018	437		$	17.38	3.6	$	2,945


(1)	Includes certain stock options with service, performance-based or market-based vesting criteria.


(2)	The aggregate intrinsic value is calculated as the difference between the closing price of our common stock as of December 31, 2017 and June 30, 2018 and the exercise price multiply by number of in-the-money options.

Schedule Of Restricted Stock Unit Activity Under Stock Plans

The following table summarizes restricted stock unit activity (in thousands, except weighted-average grant date fair value and weighted-average remaining contractual life data):



	Number of Restricted Stock Units ¹		Weighted-Average Grant Date Fair Value		Weighted-Average Remaining Service Period	Aggregate Intrinsic Value ²
Unvested as of December 31, 2017	1,745		$	14.24	2.3	$	30,313
Granted	499		$	14.03
Vested	(264	)	$	14.04
Cancelled	(112	)	$	16.05
Unvested as of June 30, 2018	1,868		$	14.92	5.8	$	41,286


(1)	Includes certain restricted stock units with service, performance-based or market-based vesting criteria.


(2)	The aggregate intrinsic value is calculated as the product of our closing stock price as of December 31, 2017 and June 30, 2018 and the number of restricted stock units outstanding as of December 31, 2017 and June 30, 2018, respectively.

Schedule Of Stock-Based Compensation Expense By Award Type

The following table summarizes stock-based compensation expense recorded during the three and six months ended June 30, 2017 and 2018 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2018		2017		2018
Common stock options	$	714	$	436	$	901	$	934
Restricted stock units	1,855		2,695		3,801		4,998
Total stock-based compensation expense	$	2,569	$	3,131	$	4,702	$	5,932

Schedule Of Stock-Based Compensation Expense By Operating Function

The following table summarizes stock-based compensation expense by operating function for the three and six months ended June 30, 2017 and 2018 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2018		2017		2018
Marketing and advertising	$	220	$	553	$	435	$	923
Customer care and enrollment	124		206		136		371
Technology and content	274		383		668		726
General and administrative	1,951		1,989		3,463		3,661
Restructuring	—		—		—		251
Total stock-based compensation expense	$	2,569	$	3,131	$	4,702	$	5,932

Income Taxes (Tables)

6 Months Ended

Jun. 30, 2018

Income Tax Disclosure [Abstract]

Schedule Of Components Of Income Tax Expense

The following table summarizes our benefit from income taxes and our effective tax rates for the three and six months ended June 30, 2017 and 2018 (in thousands, except effective tax rate):



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2018			2017			2018
Loss before benefit from income taxes	$	(10,170	)	$	(16,624	)	$	(14,006	)	$	(23,160	)
Benefit from income taxes	$	(8,664	)	$	(4,610	)	$	(13,580	)	$	(6,301	)
Effective tax rate	85.2		%	27.7		%	97.0		%	27.2		%

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Schedule Of Computation Of Basic And Diluted Net Income Per Share

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share amounts):



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2018			2017			2018
Basic:
Numerator:
Net loss	$	(1,506	)	$	(12,014	)	$	(426	)	$	(16,859	)
Denominator:
Weighted-average number of common stock shares outstanding	18,481			19,063			18,424			18,968
Net loss per share—basic:	$	(0.08	)	$	(0.63	)	$	(0.02	)	$	(0.89	)
Diluted:
Numerator:
Net loss	$	(1,506	)	$	(12,014	)	$	(426	)	$	(16,859	)
Denominator:
Net weighted average number of common stock shares outstanding	18,481			19,063			18,424			18,968
Dilutive effect of potential common stock	—			—			—			—
Total common stock shares used in per share calculation	18,481			19,063			18,424			18,968
Net loss per share—diluted:	$	(0.08	)	$	(0.63	)	$	(0.02	)	$	(0.89	)

Schedule Of Anti-dilutive Shares Excluded From Computation Of Net Income Per Share

The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net income loss per share consisted of the following (in thousands):



	Three Months Ended June 30,		Six Months Ended June 30,
	2017	2018	2017	2018
Common stock options	841	1,021	916	1,013
Restricted stock units	1,094	1,632	1,109	1,581
Total	1,935	2,653	2,025	2,594

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule Of Future Minimum Rental Payments For Operating Leases



For the Years Ending December 31,	Operating Lease Obligations		Service and Licensing Obligations		Total Obligations
2018	$	2,177	$	963	$	3,140
2019	4,966		1,681		6,647
2020	5,238		719		5,957
2021	3,769		—		3,769
2022	3,881		—		3,881
Thereafter	13,852		—		13,852
Total	$	33,883	$	3,363	$	37,246

Operating Segments, Geographic Information and Significant Customers (Tables)

6 Months Ended

Jun. 30, 2018

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table presents summary results of our operating segments for the three and six months ended June 30, 2017 and 2018 (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2018			2017			2018
Revenue
Medicare	$	24,162		$	25,468		$	49,572		$	56,231
Individual, Family and Small Business	10,404			7,189			26,550			19,496
Total revenue	$	34,566		$	32,657		$	76,122		$	75,727

Segment profit (loss)
Medicare segment profit (loss)	$	(2,013	)	$	(1,473	)	$	(2,942	)	$	1,707
Individual, Family and Small Business segment profit (loss)	2,065			(617		)	8,835			2,871
Total segment profit (loss)	52			(2,090		)	5,893			4,578
Corporate	(6,940		)	(7,994		)	(13,739		)	(15,848		)
Stock-based compensation expense	(2,569		)	(3,131		)	(4,702		)	(5,681		)
Depreciation and amortization	(751		)	(631		)	(1,513		)	(1,250		)
Change in fair value of earnout liability	—			(2,500		)	—			(2,500		)
Restructuring charges	—			(9		)	—			(1,865		)
Acquisition costs	—			(18		)	—			(76		)
Amortization of intangible assets	(260		)	(547		)	(520		)	(998		)
Other income (expense), net	298			296			575			480
Loss before benefit from income taxes	$	(10,170	)	$	(16,624	)	$	(14,006	)	$	(23,160	)

Schedule Of Long Lived Assets By Geographical Areas

Long-lived assets by geographical area as of December 31, 2017 and June 30, 2018 were as follows (in thousands):



	Dec 31,		June 30,
	2017		2018
United States	$	11,211	$	12,973
China	550		469
Total	$	11,761	$	13,442

Schedule Of Revenue By Major Customers

Carriers representing 10% or more of our total revenue for the three and six months ended June 30, 2017 and 2018 are presented in the table below:



	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2018		2017		2018
UnitedHealthcare ¹	21	%	24	%	22	%	23	%
Humana	16	%	14	%	16	%	14	%


(1)	UnitedHealthcare also includes other carriers owned by UnitedHealthcare.

Restructuring Charges (Tables)

6 Months Ended

Jun. 30, 2018

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Charges

The following table summarizes the total cash and non-cash restructuring charges recognized during the six months ended June 30, 2018 (in thousands):



Employee termination costs	$	1,605
Non-cash employee termination costs - stock-based compensation	251
Other restructuring related costs	9
Total restructuring charges	$	1,865

Schedule of Restructuring Reserve

The following table summarizes the accrued restructuring charges activity during the six months ended June 30, 2018 (in thousands):



	Six Months Ended June 30, 2018
	Beginning balance		Charges		Payments			Ending balance
Employee termination costs	$	—	$	1,605	$	(1,490	)	$	115
Accrued restructuring charges - current	$	—	$	1,605	$	(1,490	)	$	115

Summary of Business and Significant Accounting Policies - Narrative (Details) $ in Millions	3 Months Ended		20 Months Ended
	Jun. 30, 2018 USD ($) state	Jun. 30, 2017 USD ($)	Jun. 30, 2012 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of states in which the Company is licensed to market and sell health insurance \| state	50
Book-of-business transfers			$ 13.9
Book-of-business, margin earned	$ 0.4	$ 0.5
Pro Forma \| Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease, asset	31.7
Operating lease, liability	$ 31.7

Summary of Business and Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Disaggregation of Revenue [Line Items]
Commission	$ 30,646	$ 32,451	$ 71,353	$ 71,288
Other	2,011	2,115	4,374	4,834
Total revenue	32,657	34,566	75,727	76,122
Medicare
Disaggregation of Revenue [Line Items]
Commission	$ 23,808	$ 22,766	$ 52,494	$ 47,263
Medicare \| Medicare Advantage
Disaggregation of Revenue [Line Items]
LTV Commissions	7.00%	7.00%	7.00%	7.00%
Commission	$ 17,738	$ 18,677	$ 39,673	$ 37,882
Medicare \| Medicare Supplement
Disaggregation of Revenue [Line Items]
LTV Commissions	5.00%	5.00%	5.00%	5.00%
Commission	$ 5,355	$ 2,886	$ 10,947	$ 6,800
Medicare \| Medicare Part D
Disaggregation of Revenue [Line Items]
LTV Commissions	5.00%	5.00%	5.00%	5.00%
Commission	$ 715	$ 1,203	$ 1,874	$ 2,581
Individual and Family
Disaggregation of Revenue [Line Items]
Commission	$ 2,744	$ 4,622	$ 6,347	$ 11,527
Individual and Family \| Non-Qualified Health Plans
Disaggregation of Revenue [Line Items]
LTV Commissions	15.00%	15.00%	15.00%	15.00%
Commission	$ 1,069	$ 1,988	$ 2,510	$ 5,761
Individual and Family \| Qualified Health Plans
Disaggregation of Revenue [Line Items]
LTV Commissions	20.00%	20.00%	20.00%	20.00%
Commission	$ 1,675	$ 2,634	$ 3,837	$ 5,766
Ancillary
Disaggregation of Revenue [Line Items]
LTV Commissions	10.00%	10.00%	10.00%	10.00%
Commission	$ 1,713	$ 3,076	$ 7,293	$ 8,104
Ancillary \| Short-term
Disaggregation of Revenue [Line Items]
Commission	1,293	1,029	2,543	2,875
Ancillary \| Dental
Disaggregation of Revenue [Line Items]
Commission	147	1,003	1,366	2,850
Ancillary \| Vision
Disaggregation of Revenue [Line Items]
Commission	391	282	731	852
Ancillary \| Other
Disaggregation of Revenue [Line Items]
Commission	$ (118)	$ 762	$ 2,653	$ 1,527
Small Business
Disaggregation of Revenue [Line Items]
LTV Commissions	0.00%	0.00%	0.00%	0.00%
Commission	$ 1,772	$ 1,532	$ 4,131	$ 3,456
Commission Bonus
Disaggregation of Revenue [Line Items]
Commission	$ 609	$ 455	$ 1,088	$ 938

Summary of Business and Significant Accounting Policies - Revenue Recognition (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Balance Sheets
Accounts receivable	$ 846		$ 846		$ 1,475
Commissions receivable - current	88,246		88,246		109,666
Prepaid expenses and other current assets	5,441		5,441		4,305
Commissions receivable - non-current	179,150		179,150		169,751
Other assets	9,035		9,035		7,287
Accrued marketing expenses	2,742		2,742		4,693
Other current liabilities	3,523		3,523		2,008
Deferred income taxes - non-current					45,089
Other non-current liabilities	2,197		2,197		1,920
Retained earnings (accumulated benefit)	187,866		187,866		204,725
Statements of Operations
Revenue	32,657	$ 34,566	75,727	$ 76,122
Cost of revenue	151	56	303	237
Other income (expense), net	296	298	480	575
Benefit from income taxes	(4,610)	(8,664)	(6,301)	(13,580)
Net income (loss)	$ (12,014)	$ (1,506)	$ (16,859)	$ (426)
Net income (loss) per diluted share (in usd per share)	$ (0.63)	$ (0.08)	$ (0.89)	$ (0.02)
Operating Segments
Statements of Operations
Revenue	$ 32,657	$ 34,566	$ 75,727	$ 76,122
Segment profit (loss)	(2,090)	52	4,578	5,893
Operating Segments \| Medicare
Statements of Operations
Revenue	25,468	24,162	56,231	49,572
Segment profit (loss)	(1,473)	(2,013)	1,707	(2,942)
Operating Segments \| Individual, Family and Small Business
Statements of Operations
Revenue	7,189	10,404	19,496	26,550
Segment profit (loss)	$ (617)	2,065	$ 2,871	8,835
As Reported \| Operating Segments
Statements of Operations
Revenue		27,957		106,896
Segment profit (loss)		(6,703)		35,071
As Reported \| Operating Segments \| Medicare
Statements of Operations
Revenue		11,014		68,988
Segment profit (loss)		(15,107)		15,588
As Reported \| Operating Segments \| Individual, Family and Small Business
Statements of Operations
Revenue		16,943		37,908
Segment profit (loss)		8,404		19,483
Accounting Standards Update 2014-09 \| As Reported
Balance Sheets
Accounts receivable					9,894
Commissions receivable - current					0
Prepaid expenses and other current assets					4,845
Commissions receivable - non-current					0
Other assets					7,317
Accrued marketing expenses					4,088
Other current liabilities					3,815
Deferred income taxes - non-current					0
Other non-current liabilities					900
Retained earnings (accumulated benefit)					(20,796)
Statements of Operations
Revenue		27,957		106,896
Cost of revenue		204		1,833
Other income (expense), net		90		116
Benefit from income taxes		125		(1,448)
Net income (loss)		$ (17,260)		$ 16,161
Net income (loss) per diluted share (in usd per share)		$ (0.93)		$ 0.86
Accounting Standards Update 2014-09 \| ASC 606 Adoption Adjustment
Balance Sheets
Accounts receivable					(8,419)
Commissions receivable - current					109,666
Prepaid expenses and other current assets					(540)
Commissions receivable - non-current					169,751
Other assets					(30)
Accrued marketing expenses					605
Other current liabilities					(1,807)
Deferred income taxes - non-current					45,089
Other non-current liabilities					1,020
Retained earnings (accumulated benefit)					$ 225,521
Statements of Operations
Revenue		$ 6,609		$ (30,774)
Cost of revenue		(148)		(1,596)
Other income (expense), net		208		459
Benefit from income taxes		(8,789)		(12,132)
Net income (loss)		$ 15,754		$ (16,587)
Net income (loss) per diluted share (in usd per share)		$ 0.85		$ (0.90)
Accounting Standards Update 2014-09 \| ASC 606 Adoption Adjustment \| Operating Segments
Statements of Operations
Revenue		$ 6,609		$ (30,774)
Segment profit (loss)		6,755		(29,178)
Accounting Standards Update 2014-09 \| ASC 606 Adoption Adjustment \| Operating Segments \| Medicare
Statements of Operations
Revenue		13,148		(19,416)
Segment profit (loss)		13,094		(18,530)
Accounting Standards Update 2014-09 \| ASC 606 Adoption Adjustment \| Operating Segments \| Individual, Family and Small Business
Statements of Operations
Revenue		(6,539)		(11,358)
Segment profit (loss)		$ (6,339)		$ (10,648)

Acquisition - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
Acquisition - Narrative (Details) - USD ($) $ in Thousands	Jan. 22, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Business Acquisition [Line Items]
Change in fair value of earnout liability		$ 2,500	$ 0	$ 2,500	$ 0
Acquisition costs		$ 18	$ 0	$ 76	$ 0
GoMedigap
Business Acquisition [Line Items]
Cash paid	$ 15,000
Cash and cash equivalents	$ 71
Shares acquired (in shares)	294,637
Earnout consideration	$ 20,000
Earnout consideration (in shares)	589,275
Goodwill deductible period	15 years
Trade names, trademarks and website addresses
Business Acquisition [Line Items]
Weighted average remaining life				9 years 3 months 24 days
Minimum \| Trade names, trademarks and website addresses \| GoMedigap
Business Acquisition [Line Items]
Weighted average remaining life				3 years
Maximum \| Trade names, trademarks and website addresses \| GoMedigap
Business Acquisition [Line Items]
Weighted average remaining life				10 years

Acquisition - Purchase Price Allocation (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 22, 2018	Jun. 30, 2018	Dec. 31, 2017
Allocation
Goodwill		$ 40,233	$ 14,096
Share price (usd per share)	$ 18.99
GoMedigap
Acquisition Consideration
Cash paid	$ 15,000
Fair value of equity awards issued to GoMedigap members	5,595
Estimated fair value of earnout liability	27,700
Purchase price	48,295
Allocation
Cash and cash equivalents	71
Commission receivable - current	4,371
Prepaid expenses and other current assets	11
Commission receivable - non-current	11,103
Property and equipment, net	174
Accounts payable	(110)
Accrued compensation and benefits	(132)
Other current liabilities	(131)
Net tangible assets acquired	15,357
Intangible assets	6,800
Goodwill	26,138
Total intangible assets acquired	32,938
Total net assets acquired	48,295
Technology \| GoMedigap
Allocation
Intangible assets	2,000
Trade names, trademarks and website addresses \| GoMedigap
Allocation
Intangible assets	$ 4,800

Balance Sheet Accounts - Schedule of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Balance Sheet Related Disclosures [Abstract]
Cash	$ 7,396	$ 5,098
Money market funds	23,378	35,195
Total cash and cash equivalents	$ 30,774	$ 40,293	$ 66,080	$ 61,781

Balance Sheet Accounts - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Balance Sheet Related Disclosures [Abstract]
Prepaid maintenance contracts	$ 1,849	$ 1,945
Prepaid insurance	1,169	490
Prepaid rent	508	311
Other current assets	1,915	1,559
Total prepaid expenses and other current assets	$ 5,441	$ 4,305

Balance Sheet Accounts - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Schedule Of Intangible Assets [Line Items]
Gross Carrying Amount	$ 19,507	$ 12,707
Accumulated Amortization	(11,279)	(10,281)
Total	8,228	2,426
Indefinite-lived trademarks and domain names	5,114	5,114
Intangible assets	13,342	7,540
Technology
Schedule Of Intangible Assets [Line Items]
Gross Carrying Amount	3,700	1,700
Accumulated Amortization	(1,978)	(1,700)
Total	$ 1,722	0
Weighted average remaining life	2 years 7 months 6 days
Pharmacy and customer relationships
Schedule Of Intangible Assets [Line Items]
Gross Carrying Amount	$ 10,100	10,100
Accumulated Amortization	(8,358)	(7,884)
Total	$ 1,742	2,216
Weighted average remaining life	1 year 9 months 18 days
Trade names, trademarks and website addresses
Schedule Of Intangible Assets [Line Items]
Gross Carrying Amount	$ 5,707	907
Accumulated Amortization	(943)	(697)
Total	$ 4,764	$ 210
Weighted average remaining life	9 years 3 months 24 days

Balance Sheet Accounts - Schedule of Intangible Asset Future Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Fiscal Year Maturity [Abstract]
2018	$ 1,092
2019	2,187
2020	1,494
2021	535
2022	480
Thereafter	2,440
Total	8,228	$ 2,426
Technology
Fiscal Year Maturity [Abstract]
2018	333
2019	667
2020	667
2021	55
2022	0
Thereafter	0
Total	1,722	0
Pharmacy and customer relationships
Fiscal Year Maturity [Abstract]
2018	475
2019	950
2020	317
2021	0
2022	0
Thereafter	0
Total	1,742	2,216
Trade names, trademarks and website addresses
Fiscal Year Maturity [Abstract]
2018	284
2019	570
2020	510
2021	480
2022	480
Thereafter	2,440
Total	$ 4,764	$ 210

Stockholder's Equity - Schedule of Stock Plan Activity (Details) - 2014 Equity Incentive Plan shares in Thousands	6 Months Ended
	Jun. 30, 2018 shares
Share-based Compensation Arrangement by Share-based Payment Award, Movement in Shares Available for Grant [Roll Forward]
Shares available for grant (in shares)	1,409
Restricted stock units granted (in shares)	(499)
Options granted (in shares)	(111)
Restricted stock units cancelled (in shares)	112
Options cancelled (in shares)	17
Shares available for grant (in shares)	928

Stockholder's Equity - Schedule of Option Activity Under Stock Plans (Details) - Common stock options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Number of Stock Options
Stock options issued and outstanding (in shares)	983
Granted (in shares)	111
Exercised (in shares)	(46)
Cancelled (in shares)	(95)
Stock options issued and outstanding (in shares)	953	983
Options vested and expected to vest (in shares)	909
Options exercisable (in shares)	437
Weighted Average Exercise Price
Weighted-average exercise price, balance outstanding (in dollars per share)	$ 17.38
Granted (in dollars per share)	15.69
Exercised (in dollars per share)	13.47
Cancelled (in dollars per share)	25.19
Weighted-average exercise price, balance outstanding (in dollars per share)	16.45	$ 17.38
Weighted-average exercise price, vested and expected to vest (in dollars per share)	16.45
Weighted-average exercise price, exercisable (in dollars per share)	$ 17.38
Weighted-average remaining contractual life (years), balance outstanding	4 years 8 months 19 days	4 years 7 months 6 days
Weighted-average remaining contractual life (years), vested and expected to Vest	4 years 7 months 28 days
Weighted-average remaining contractual life (years), exercisable	3 years 6 months 22 days
Aggregate intrinsic value, balance outstanding	$ 6,344	$ 2,522
Aggregate intrinsic value, vested and expected to vest	6,083
Aggregate intrinsic value, exercisable	$ 2,945

Stockholder's Equity - Schedule of Restricted Stock Unit Activity Under Stock Plans (Details) - Restricted stock units - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Number of Restricted Stock Units
Restricted Stock Units Issued And Outstanding (in shares)	1,745
Granted (in shares)	499
Vested (in shares)	(264)
Cancelled (in shares)	(112)
Restricted Stock Units Issued And Outstanding (in shares)	1,868	1,745
Weighted-Average Grant Date Fair Value
Weighted-Average Grant Date Fair Value, Balance (in dollars per share)	$ 14.24
Granted (in dollars per share)	14.03
Vested (in dollars per share)	14.04
Cancelled (in dollars per share)	16.05
Weighted-Average Grant Date Fair Value, Balance (in dollars per share)	$ 14.92	$ 14.24
Weighted-Average Remaining Service Period	5 years 9 months 7 days	2 years 3 months 14 days
Aggregate Intrinsic Value	$ 41,286	$ 30,313

Stockholder's Equity - Narrative (Details) - USD ($) $ in Millions	6 Months Ended	51 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Number of shares repurchased under share repurchase plan (in shares)	0	10,663,888
Treasury shares that were previously surrendered by employees to satisfy tax withholdings (in shares)	660,493
Treasury stock (in shares)	11,324,381	11,324,381	11,237,995
Incremental stock-based compensation expense	$ 0.3

Stockholder's Equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 3,131	$ 2,569	$ 5,932	$ 4,702
Marketing and advertising
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	553	220	923	435
Customer care and enrollment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	206	124	371	136
Technology and content
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	383	274	726	668
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,989	1,951	3,661	3,463
Restructuring
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	0	0	251	0
Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	436	714	934	901
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,695	$ 1,855	$ 4,998	$ 3,801

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Loss before benefit from income taxes	$ (16,624)	$ (10,170)	$ (23,160)	$ (14,006)
Benefit from income taxes	$ (4,610)	$ (8,664)	$ (6,301)	$ (13,580)
Effective tax rate	27.70%	85.20%	27.20%	97.00%

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 4,610	$ 8,664	$ 6,301	$ 13,580
Effective tax rate	27.70%	85.20%	27.20%	97.00%

Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Numerator:
Net loss	$ (12,014)	$ (1,506)	$ (16,859)	$ (426)
Denominator:
Weighted-average number of common stock shares outstanding (in shares)	19,063	18,481	18,968	18,424
Dilutive effect of potential common stock (in shares)	0	0	0	0
Net loss per share-basic (in usd per share)	$ (0.63)	$ (0.08)	$ (0.89)	$ (0.02)
Total common stock shares used in per share calculation (in shares)	19,063	18,481	18,968	18,424
Net income (loss) per diluted share (in usd per share)	$ (0.63)	$ (0.08)	$ (0.89)	$ (0.02)

Net Loss Per Share - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,653	1,935	2,594	2,025
Common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,021	841	1,013	916
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,632	1,094	1,581	1,109

Commitments and Contingencies - Narrative (Details) - Breach of Contract - Maximum	1 Months Ended
	Jul. 31, 2017 USD ($)
Loss Contingencies [Line Items]
Litigation settlement, amount awarded	$ 250,000
Litigation settlement, amount awarded, per individual	$ 2,500
Litigation settlement, amount awarded, period of extended protection (in years)	1 year
Litigation settlement, amount awarded, period of protection	3 years
Litigation settlement, expense	$ 245,000

Commitments and Contingencies - Operating lease (Details) $ in Thousands		1 Months Ended	3 Months Ended
	Apr. 25, 2018 USD ($) ft²	Mar. 31, 2018 USD ($) ft²	Jun. 30, 2018 USD ($)	Mar. 31, 2012 USD ($)
Commitments And Contingencies Disclosure [Line Items]
Future minimum payments related to operating lease			$ 37,246
Santa Clara, California
Commitments And Contingencies Disclosure [Line Items]
Office space, square feet \| ft²	32,492
Operating lease, term	123 months
Future minimum payments related to operating lease	$ 17,700
Austin, Texas
Commitments And Contingencies Disclosure [Line Items]
Office space, square feet \| ft²		27,000
Operating lease, term		90 months
Future minimum payments related to operating lease		$ 4,500
Standby Letters of Credit \| Santa Clara, California
Commitments And Contingencies Disclosure [Line Items]
Letters of credit, amount outstanding	$ 1,500
Standby Letters of Credit \| Austin, Texas
Commitments And Contingencies Disclosure [Line Items]
Letters of credit, amount outstanding		$ 600
Standby Letters of Credit \| Mountain View, California
Commitments And Contingencies Disclosure [Line Items]
Letters of credit, amount outstanding			$ 100	$ 600
$1.5 Million Standby Letter of Credit \| Standby Letters of Credit \| Santa Clara, California
Commitments And Contingencies Disclosure [Line Items]
Incremental reduction rate			20.00%
Reduction of standby letter of credit amount, Percentage sixth year	8.00%
$.6 Million Standby Letter of Credit \| Mountain View, California
Commitments And Contingencies Disclosure [Line Items]
Incremental reduction rate				25.00%

Commitments and Contingencies - Schedule of Future Minimum Obligations (Details) $ in Thousands	Jun. 30, 2018 USD ($)
Commitments And Contingencies Disclosure [Line Items]
2018	$ 3,140
2019	6,647
2020	5,957
2021	3,769
2022	3,881
Thereafter	13,852
Total	37,246
Operating Lease Obligations
Commitments And Contingencies Disclosure [Line Items]
2018	2,177
2019	4,966
2020	5,238
2021	3,769
2022	3,881
Thereafter	13,852
Total	33,883
Service and Licensing Obligations
Commitments And Contingencies Disclosure [Line Items]
2018	963
2019	1,681
2020	719
2021	0
2022	0
Thereafter	0
Total	$ 3,363

Operating Segments, Geographic Information and Significant Customers (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) segment	Jun. 30, 2017 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments \| segment			2
Revenue	$ 32,657	$ 34,566	$ 75,727	$ 76,122
Stock-based compensation expense	(3,131)	(2,569)	(5,681)	(4,702)
Depreciation and amortization	(631)	(751)	(1,250)	(1,513)
Change in fair value of earnout liability	(2,500)	0	(2,500)	0
Restructuring benefit	(9)	0	(1,865)	0
Acquisition costs	(18)	0	(76)	0
Amortization of intangible assets	(547)	(260)	(998)	(520)
Other income (expense), net	296	298	480	575
Loss before benefit from income taxes	(16,624)	(10,170)	(23,160)	(14,006)
Operating Segments
Segment Reporting Information [Line Items]
Revenue	32,657	34,566	75,727	76,122
Segment profit (loss)	(2,090)	52	4,578	5,893
Operating Segments \| Medicare
Segment Reporting Information [Line Items]
Revenue	25,468	24,162	56,231	49,572
Segment profit (loss)	(1,473)	(2,013)	1,707	(2,942)
Operating Segments \| Individual, Family and Small Business
Segment Reporting Information [Line Items]
Revenue	7,189	10,404	19,496	26,550
Segment profit (loss)	(617)	2,065	2,871	8,835
Corporate
Segment Reporting Information [Line Items]
Segment profit (loss)	$ (7,994)	$ (6,940)	$ (15,848)	$ (13,739)

Operating Segments, Geographic Information and Significant Customers - Schedule Of Long-Lived Assets By Geographical Area (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Total	$ 13,442	$ 11,761
United States
Segment Reporting Information [Line Items]
Total	12,973	11,211
China
Segment Reporting Information [Line Items]
Total	$ 469	$ 550

Operating Segments, Geographic Information and Significant Customers - Schedule of Revenue by Major Customers (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue, Major Customer [Line Items]
Commissions receivable	$ 267.4		$ 267.4
UnitedHealthcare
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	24.00%	21.00%	23.00%	22.00%
Humana
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	14.00%	16.00%	14.00%	16.00%

Restructuring Charges (Details) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
Restructuring Charges (Details) $ in Thousands	Feb. 28, 2018 employee	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)
Restructuring Cost and Reserve [Line Items]
Positions eliminated \| employee	110
Percentage of total workforce	10.00%
Restructuring Reserve [Roll Forward]
Charges		$ 9	$ 0	$ 1,865	$ 0
Employee termination costs
Restructuring Cost and Reserve [Line Items]
Expected cost		1,600		1,600
Non-cash employee termination costs - stock-based compensation
Restructuring Cost and Reserve [Line Items]
Expected cost		300		300
Other restructuring related costs
Restructuring Reserve [Roll Forward]
Charges				9
Cash Restructuring Charges
Restructuring Reserve [Roll Forward]
Beginning balance				0
Charges				1,605
Payments				(1,490)
Ending balance		115		115
Cash Restructuring Charges \| Employee termination costs
Restructuring Reserve [Roll Forward]
Beginning balance				0
Charges				1,605
Payments				(1,490)
Ending balance		$ 115		$ 115

Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	$ 23,378	$ 35,195
Total liabilities measured and recorded at fair value	30,200	0
Carrying Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	23,378	35,195
Total liabilities measured and recorded at fair value	30,200	0
Fair Value \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	23,378	35,195
Total liabilities measured and recorded at fair value	0	0
Fair Value \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	0
Total liabilities measured and recorded at fair value	30,200
Earnout liability - current
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	15,766	0
Earnout liability - current \| Carrying Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	15,766	0
Earnout liability - current \| Fair Value \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	0	0
Earnout liability - current \| Fair Value \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	15,766
Earnout liability - non-current
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	14,434	0
Earnout liability - non-current \| Carrying Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	14,434	0
Earnout liability - non-current \| Fair Value \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	0	0
Earnout liability - non-current \| Fair Value \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured and recorded at fair value	14,434
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	23,378	35,195
Money market funds \| Carrying Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	23,378	35,195
Money market funds \| Fair Value \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	23,378	$ 35,195
Money market funds \| Fair Value \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured and recorded at fair value	$ 0